Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

Erythema Clinical Trial

Official title:

Efficacy of a Skin Protectant Textile for the Management of Skin Fold Conditions

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05742347
• Other study ID #: MED-2021-DIV80-006
• Status: Enrolling by invitation
• Phase: N/A
• Start date: July 1, 2022
• Est. completion date: June 9, 2025

Study information

• Verified date: April 2023
• Source: Medline Industries
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy of the DriGo skin protectant textile (SPT) to manage erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor associated with skin folds (henceforth together referred to as "skin fold conditions"). Participants will be patients with skin fold conditions, which will be treated with the SPT. Healthcare providers will apply the SPT to the participants' target areas. An independent licensed clinician with experience in identifying and treating skin fold conditions, will use photographs of the skin folds and other skin-on-skin contact areas (henceforth referred to as "target area[s]") to assess the status of erythema, maceration, denudation, and satellite lesions in the target areas when the SPT is first applied (Day 0), and on Days 1, 3, and 5, during SPT changes. The Principal Investigator (PI) or qualified designee will take photographs of the target areas and assess moisture and odor in these areas. Participants will provide their impressions of pain, itching and burning in the target area(s) on the same days as the skin fold condition photography. In addition, the study will include feedback from the Health Care Providers (HCPs) about the SPT and overall experience of the participants with the SPT.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 80
• Est. completion date: June 9, 2025
• Est. primary completion date: June 9, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Individuals = 18 years of age.

• Individuals who have evidence of one or more of the following skin fold conditions:

erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor.

• Individuals whose treatment plan permits assessment of the skin fold condition(s) for up to six days.

Exclusion Criteria:

• Individuals whose target area(s) are being managed with topical treatments such as antibiotics, antifungals, ointments including skin protectants, anti-itch products, anoperineal dressings or absorbent pads (eg, ARD®).

• Individuals with a known allergy or sensitivity to the ingredients in the SPT, such as the fabric or H2O2, as well as the tape that may be used to secure the SPT.

Related Conditions & MeSH terms

• Erythema
• Lesion Skin

Intervention

Device:
• DriGo Skin Protectant Textile
All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.

Locations

Country	Name	City	State
United States	Bryan Medical Center	Lincoln	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
Medline Industries

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to skin fold healing	Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using 1. Likert scales developed for erythema, maceration, denudation, and satellite lesions. Scoring of the target area(s) done by a third-party clinician using the Likert scale(s) and photographs taken by the PI or qualified designee on Day 0, and on Days 1, 3, and 5, during SPT changes.	5 days
Primary	To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to participant assessment	Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using assessment of odor in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale. Participant assessment of discomfort (pain, itching, and burning) assessment using a VAS on Day 0, and on Days 1, 3, and 5, during SPT changes. Participants will also be asked to identify the most prominent type of discomfort in the skin fold: pain, itching, or burning.	5 days
Secondary	To gather PI or qualified designee's assessment of moisture control in the target areas	PI or qualified designee survey response for moisture in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale (5-scale likert ranging from absent to large).	5 days
Secondary	To assess HCP feedback on the SPT	HCP survey responses on Day 5 regarding feedback about the SPT, using a VAS (0-100 scale; 0 being strongly disagree, 100 being strongly agree)	5 days
Secondary	To assess the overall participant experience with the SPT	Participant responses on Day 5 regarding their experience with the SPT, using a VAS (0-100 scale; 0 being no discomfort, 100 being intense discomfort)	5 days